Pharvaris’ deucrictibant shows positive results in HAE attacks

Pharvaris announced the upcoming presentation of two posters at the American Academy of Allergy, Asthma, & Immunology 2024 Annual Scientific Meeting in Washington D.C. February 23-26. The abstracts have been published in an online supplement to The Journal of Allergy and Clinical Immunology. The first poster reports on CHAPTER-1, a two-part, Phase 2 study evaluating the efficacy, safety, and tolerability of deucrictibant for long-term prophylaxis against angioedema attacks in hereditary angioedema, or HAE, type 1 and type 2. Analysis of the primary endpoint demonstrated that deucrictibant significantly reduced the monthly attack rate by 84.5% in participants dosed at 40 mg/day and 79.3% in participants dosed at 20 mg/day compared to placebo. Analyses of secondary endpoints demonstrated that treatment with deucrictibant reduced the occurrence of moderate and severe attacks and of attacks treated with on-demand medication compared to placebo, and a consistent reduction in monthly attack rate was observed with deucrictibant treatment regardless of baseline attack rate. Deucrictibant was well tolerated at both doses. A second poster will be presented during the poster session on February 23.